Immunocore and Lilly team up on combination trial for melanoma

29 June 2015

Privately-owned British company Immunocore and US drug major Eli Lilly (NYSE: LLY) have entered into an immunotherapy-based trial collaboration for Immunocore’s IMCgp100 in combination with Lilly’s galunisertib and merestinib in melanoma.

IMCgp100, Immunocore’s lead T-cell receptor-based investigational therapeutic, is being investigated in combination with Lilly’s drugs in the treatment of metastatic cutaneous and uveal melanomas.

Immunocore and Lilly will conduct a Phase Ib/II clinical study evaluating the safety and efficacy of IMCgp100 in combination with galunisertib in metastatic cutaneous melanoma. A second Phase Ib/II study will be conducted on the combination of IMCgp100 with merestinib in metastatic uveal melanoma. Lilly will be the trial sponsor and studies will begin in 2016. No financial terms have been disclosed.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK